Genetic strategies for the personalization of antipsychotic treatment

References

• Arranz MJ, Collier DA, Kerwin RVV. Pharmacogenetics for the individualization of psychiatric treatment. Am. J: Pharmacogenomits 1(1), 3–10 (2001).
   Google Scholar
• Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev Pharmacol Toxicol 37,269–296 (1997).
   PubMed Web of Science ®Google Scholar
• Nebert DW, Dieter MZ. The evolution of drug metabolism. Pharmacology 61(3), 124–135 (2000).
   PubMed Web of Science ®Google Scholar
• •• Review of drug metabolism and itsinfluence on drug adverse reactions.
   Google Scholar
• Arranz MJ, Kerwin RVV. Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment. Ann. Merl 32(5), 128–133 (2000).
   PubMedGoogle Scholar
• Kawanishi Y, Tachikawa H, Suzuki T Pharmacogenomics and schizophrenia. Eur Pharmacol 410,227–241 (2000).
   PubMed Web of Science ®Google Scholar
• • Review of genetic variants in neurotransmitter receptors and their influence on antipsychotic response.
   Google Scholar
• Segman RH, Heresco-Levy U, Finkel B et al Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3g1y alleles to susceptibility. Psychopharmacol 152(4), 408–413 (2000).
   Google Scholar
• Ozdemir V, Basile VS, Masellis M, Kennedy JL. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. I Biochem. Biophys Meth. 47(1–2), 151–157 (2001).
   Google Scholar
• Bertilsson L, Dahl ML. Polymorphic drug oxidation— Relevance to the treatment of psychiatric disorders. CNS Drugs5 (3), 220–223 (1996).
   Web of Science ®Google Scholar
• Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW. Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 10,91–93 (2000).
   Google Scholar
• Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogeneties 11(3), 237–245 (2001).
   Google Scholar
• Farm n FM, Omiecinski CJ. Regiospecific expression of cytochrome P450s and microsomal epoxide hydrolase in human brain tissue. J: Toxicol Environ. Health 40(2–3), 317–335 (1993).
   Google Scholar
• Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4 and CYP2D6*6 alleles by tetra-primer PCR and of the CYP3D6*5 allele by multiplex long PCR. Clin. Chem. 46(8), 1072–1077 (2000).
   Google Scholar
• Roberts R, Sullivan P, Joyce P, Kennedy MA. Rapid and comprehensive determination of cytochrome P450CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction. Hum. Nlutat. 16(1), 77–85 (2000).
   Google Scholar
• Ferguson RJ, De Morais SMF, Benhamou S etal A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. j Pharmacol Exp. Ther. 284(1), 356–361 (1998).
   Google Scholar
• Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 356,1667–1771 (2000).
   PubMed Web of Science ®Google Scholar
• • Review of influence of CYP polymorphisms on drug treatment.
   Google Scholar
• Cascorbi I, Gerloff T, Johne A etal Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Phatmacol Ther. 69(3), 169–174 (2001).
   Google Scholar
• Kerwin RW, Osborne S. Antipsychotic drugs. Medicine 28 (4), 23–25 (2000) .
   Google Scholar
• Cunningham Owens DG. A Guide to the Extrapyramidal Side Effects of Antipsychotic Drugs. Cambridge University Press, Cambridge, UK (1999).
   Google Scholar
• Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacol 21 (2)s106—s115 (1999).
   Google Scholar
• •• Hypothesis of mechanism of action ofantipsychotic drugs.
   Google Scholar
• Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophrenia Res. 37(1), 1–11 (1999).
   PubMed Web of Science ®Google Scholar
• Schafer M, Rujescu D, Giegling I, etal Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J. Psychiatry158(5), 802–804 (2001).
   Google Scholar
• Basile VS, Masellis M, Badri F et al Association of the Msc I polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia Neumpsychophatmacology21, 17–27 (1999).
   Google Scholar
• Segman R, Neeman T, Herseco-Levy U et al Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mal Psychiatry 4, 247–253 (1999).
   PubMed Web of Science ®Google Scholar
• Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mal Psychiatry2(2), 139–145 (1997).
   Google Scholar
• Lovlie R, Thara R, Padmavathi R, Steen VM, McCreadie RG. Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. Mal Psychiatry 6, 7–8 (2001).
   Google Scholar
• Kaiser R, Konneker M, Henneken M eta]. Dopamine D4 receptor 48-bp repeat polymorphisms: no association with response to antipsychotic treatment but association with catatonic schizophrenia. Mol Psychiatiy5(4), 418–424 (2000).
   Google Scholar
• Arranz MJ, Collier DA, Sodhi M eta]. Association between clozapine response and allelic variation in the 5-HT2A receptor gene. Lancet 346,281–282 (1995).
   Google Scholar
• • First report on the influence of genetic polymorphisms in neurotransmitter receptors on antipsychotic response.
   Google Scholar
• Arranz MJ, Collier DA, Munro J eta]. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neumsci. Lett. 217,177-178 (1996).
   Google Scholar
• Masellis M, Basile VS, Meltzer HY etal Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychophatmacology19,123–132 (1998).
   PubMed Web of Science ®Google Scholar
• Sodhi M, Arranz MJ, Curtis D etal Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neumreport 7,169–172 (1995).
   PubMed Web of Science ®Google Scholar
• Yu YWY, Tsai S-J, Lin C-H, Hsu C-P, Ynakg K-H, Hong C-J. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport10, 1231–1233 (1999).
   Google Scholar
• Sodhi M, Sham P, Makoff A etal Replication and meta-analysis of alleleic association of a 5-HT2C receptor polymorphism with good response to clozapine. Mal Psychiatry4(1), 225–226 (1999).
   Google Scholar
• Rietschel M, Kennedy JL, Macciardi F, Meltzer HY. Application of pharmacogenetics to psychotic disorders: the first consensus conference. Schizophrenia Res. 37,191–196 (1999).
   PubMedGoogle Scholar
• Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol. fiychiatry 47 (3), 252–266 (2000).
   PubMed Web of Science ®Google Scholar
• Arranz MJ, Munro J, Birkett J etal Pharmacogenetic prediction of clozapine response. Lancet355, 1615–1616 (2000).
   PubMed Web of Science ®Google Scholar
• •• First genetic prediction test forantipsychotic response.
   Google Scholar
• Williams J, Spurlock J, McGuffin P et al Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine Type 2a-receptor gene. Lancet 347,1294–1296 (1996).
   PubMed Web of Science ®Google Scholar
• Lin CH, Tsai SJ, Yu YVV etal No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport10(1), 57–60 (1999).
   Google Scholar
• Inayama Y, Yoneda H, Sakai T etal Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J. Med. Genet. 67(1), 103–105 (1996).
   Google Scholar
• Lander ES, Linton LM, Birren B et al Initial sequencing and analysis of the human genome. Nature 409 (6822), 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• • First draft of the human genome.
   Google Scholar
• Sachidanandam R, Weissman D, Schmidt SC etal A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409(6822), 928–933 (2001).
   Google Scholar
• • First map of single nucleotide mutations in human genome.
   Google Scholar
• Crocq MA, Mant R, Asherson P etal Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J. Med. Genet. 29(12), 858–860 (1992).
   Google Scholar
• Spurlock G, Has A, Holmans P etal A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mal Pwchiatry3(1), 42–49 (1998).
   Google Scholar
• Warren JT, Jr., Peacock ML, Rodriguez LC, Fink JK. An MspI polymorphism in the hyman serotonin receptor gene (HTR2) : detection by DGGE and RFLP analysis. Hum. Mal Genet. 2(3), 338 (1993).
   Google Scholar
• Erdmann J, Shimron-Abarbanell D, Rietschel M etal Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum. Genet. 97(5), 614–619 (1996).
   Google Scholar
• Lappalainen J, Zhang L, Dean M eta]. Identification, expression and pharmacology of a Cys23-SeR23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomic527(2), 274–279 (1995).
   Google Scholar
• Deckert J, Meyer J, Catalano M eta]. Novel 5 '-regulatory region polymorphisms of the 5-HT2C receptor gene: association study with panic disorder. Int. J: Neuropsychopharmacol. 3(4), 321–325 (2000).
   Google Scholar
• Collier DA, Stober G, Li T etal A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol. Psychiatry 1(6), 453–460 (1996).
   PubMed Web of Science ®Google Scholar
• Mancama D, Arranz MJ, Munro J, Makoff A, Kerwin RW. The histamine 1 and histamine 2 receptor genes- candidates for schizophrenia and clozapine response. GeneSarenl, 29–34 (2000).
   Google Scholar